SLU-PP-332

A small synthetic molecule from Saint Louis University (hence SLU) that activates the estrogen-related receptors ERRα, β and γ. It is studied as an exercise mimetic: it turns on muscle genes that endurance training turns on.

No. It is a small organic molecule, C18H14N2O2 at about 290 g/mol, with no amino acids. Vendors list it with peptides because the same buyers want it.

In mice it raised energy use and fat burning, increased oxidative muscle fibres, extended treadmill running, reduced fat gain in obese mice, protected failing hearts and reversed kidney ageing markers. None of this has been tested in people.

Probably poorly. The lab that made it says SLU-PP-332 lacks oral bioavailability, and built SLU-PP-915 as the oral version. Every animal result came from injection into the abdomen. That matters because most product sold is tablets or capsules.

Injection matches the animal studies, though mice got it into the abdominal cavity, not under the skin. Oral is easier but rests on a compound its developers call not orally bioavailable. No human data settle it either way.

No human dose exists. Community injection doses run from 250 mcg to 1.5 mg a day, 1 to 5 mg a day split, up to 5 to 10 mg once daily. Oral users take 25 to 100 mg from 50 mg tablets. Mice got 25 to 50 mg/kg.

Some guides size the dose to fit a 5 mg vial (hundreds of mcg), others scale up the mouse dose by body surface area (hundreds of mg). One competitor puts the gap at roughly 1,000-fold. Neither approach has been tested in people.

A common choice is 2 mL of bacteriostatic water, giving 2.5 mg/mL; 10 units on a U-100 syringe is then 250 mcg. Guides also use 1 mL or 3 mL.

Not published. In mice it was still in plasma and muscle 2 to 6 hours after one injection, which is why the studies dosed twice a day. A competitor's 1.5-hour figure has no cited source.

No human data. Mice showed no overt toxicity and no liver enzyme rise. Users report early fatigue, sleep changes or a wired feeling, a higher resting heart rate in some, stomach upset with oral use and injection-site reactions.

In obese mice, yes: after 28 days they weighed about 12% less and gained under 0.5 g of fat versus about 5 g in controls, with no change in food intake. In normal chow-fed mice, total body weight did not change. No human data.

After 7 days at 50 mg/kg twice daily, sedentary mice ran about 70% longer and 45% farther than untreated mice. The effect disappeared in mice lacking muscle ERRα.

SLU-PP-332 is a synthetic small molecule acting on ERR nuclear receptors; MOTS-c is a natural mitochondrial peptide acting through AMPK. Users often stack them. Neither has human efficacy trials.

Not FDA approved, no human trial registered, and not on FDA's compounding lists. It is sold as a research chemical, not a drug or supplement.

WADA does not name it on the 2026 List and has no ERR-agonist class. Its S0 class bans any compound still in development with no human approval, which on plain wording could include it, so we list the status as unknown. Anti-doping labs in Cologne and Los Angeles published ways to detect its metabolites in 2026.

Mostly endurance and cardio gains, often next to AICAR or MOTS-c, and use alongside retatrutide for fat loss. Reports are uncontrolled. PeptIQ app check-ins rate it mixed far more than favorable.